October 7, 2020
White House Approves Tougher Rules for COVID-19 Vaccine Development
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Following weeks of delay, the White House on Tuesday approved tough new rules for COVID-19 vaccine developers that will make it unlikely that a vaccine will be approved before Election Day. The approval came only after the U.S. Food and Drug Administration published the updated guidelines on its...
Six States Set Records for COVID-19 Hospitalizations
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Records for COVID-19 hospitalizations were set Tuesday in six states — Arkansas, Montana, North Dakota, South Dakota, Wisconsin, and Wyoming. Another state, Oklahoma, had its highest number of hospitalizations since July, according to The Washington Post. Wyoming’s 36.7 percent increase since last week in its rolling seven-week average...
Company Seeks FDA Emergency Approval for COVID-19 Antibody Therapy
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19. The request to the U.S. Food and Drug Administration is based on partial clinical trial findings suggesting the drug reduced symptoms, the amount of virus, hospitalizations, and emergency department visits...
Neurologic Manifestations Seen in Most Hospitalized With COVID-19
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Neurologic manifestations are common in COVID-19, occurring in 82.3 percent of hospitalized patients, according to a study published online Oct. 5 in the Annals of Clinical and Translational Neurology. Eric M. Liotta, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues characterized neurologic manifestations,...
Lopinavir-Ritonavir No Benefit in Patients Admitted With COVID-19
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Lopinavir-ritonavir is not associated with reductions in 28-day mortality or duration of hospital stay among patients admitted to the hospital with COVID-19, according to a study published online Oct. 5 in The Lancet. Peter W. Horby, M.D., Ph.D., and colleagues on behalf of the RECOVERY Collaborative Group conducted...
Review: Estimated Prevalence of VTE 14.1 Percent in COVID-19
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — The overall prevalence of venous thromboembolism (VTE) in patients with COVID-19 is estimated to be 14.1 percent, with a higher prevalence for patients in the intensive care unit (ICU), according to a review published online Sep. 25 in Research and Practice in Thrombosis and Haemostasis. Stephan Nopp, M.D.,...